A Study Evaluating the Safety and Efficacy of KITE-585 in Subjects With Relapsed/Refractory Multiple Myeloma

Participants with relapsed/refractory multiple myeloma can participate if all eligibility
criteria are met. Tests required to determine eligibility include disease assessments, a
physical exam, ECG and echocardiogram of the heart, brain MRI, and blood draws. Eligible
participants have white blood cells collected by apheresis. These cells are genetically
modified to make the experimental treatment KITE-585. Participants receive chemotherapy prior
to the KITE-585 infusion. After the KITE-585 infusion, participants will be followed for side
effects and effect of KITE-585 on their myeloma. Study procedures may be performed while
hospitalized and/or in the outpatient setting.

Key Inclusion Criteria:

1. Measurable relapsed or refractory myeloma as defined by the International Myeloma
Working Group (IMWG) Consensus Criteria following treatment with at least 3 lines of
therapy including with both a proteasome inhibitor (PI) and an immunomodulatory drug
(IMiD), or progressive myeloma that is refractory to a regimen containing both a PI
and an IMiD.

2. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

3. Adequate bone marrow, renal, hepatic, pulmonary, and cardiac function defined as:

- Absolute neutrophil count (ANC) ≥ 1,000/µL

- Platelet count ≥ 75,000/µL

- Absolute lymphocyte count ≥ 100/µL

- Creatinine clearance above limits set in the protocol for each cohort

- Normal cardiac function as assessed by electrocardiogram (ECG) and echocardiogram

- Baseline oxygen saturation > 92% on room air and no clinically significant
pleural effusion

Key Exclusion Criteria:

1. Plasma cell leukemia

2. Non-secretory multiple myeloma

3. History of Central nervous system (CNS) involvement by multiple myeloma (MM)

4. Prior chimeric antigen receptor (CAR) therapy or other genetically modified T cells

5. Inadequate washout from prior therapy

6. Autologous stem cell transplant within 6 weeks before enrollment or any history of
allogenic transplant

7. History of active autoimmune disease

8. History of deep vein thrombosis or pulmonary embolism requiring systemic
anticoagulation within 6 months before enrollment

9. Recent history of other (non multiple myeloma) cancer

10. Active viral, fungal, bacterial or other infection

Note: Other protocol defined Inclusion/Exclusion criteria may apply